Infusion Associates PC

1. Takeda Pharmaceuticals U.S.A., Inc. $480,840 9 payments
2. Amicus Therapeutics, Inc. $38,851 14 payments
3. Genzyme Corporation $13,839 3 payments

1. EntyvioVedolizumab Long Term Study $180,540 3 payments
2. Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn's Disease $171,600 3 payments
3. Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn's Disease $128,700 3 payments
4. ZIP Study - A Study to Evaluate the PK, Safety, Efficacy, and PD With ATB200/AT2221 in LOPD Subjects Aged 12 to <18 $14,000 1 payment
5. PASS to Assess Long-term Safety in Patients with Pompe disease in the Commercial Setting $13,839 3 payments
6. ZIP Study - A Study to Evaluate the PK, Safety, Efficacy, and PD With ATB200/AT2221 in LOPD Subjects Aged 12 to <18 $9,120 3 payments
7. Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease $6,013 6 payments
8. First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2258 $4,618 1 payment
9. First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 $4,100 2 payments
10. ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD $1,000 1 payment

1. Other $180,540 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.